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INTRODUCTION 
Ischemic disease causes death and disability in developed 
countries more than any other disease and imposes high 
economical costs. In Iran, myocardial infarction is the 
first cause of death in people over 35 years. By 
considering prevalence of cardiovascular diseases all 
around the world, using new methods in biomedical 
researches have been considered.
1
 The most common 
coronary artery disease is myocardial infarction which 
happens due to coronary artery obstruction and 
myocardial ischemia. Myocardial infarction is one of the 
main reasons of death in cardiovascular patients. In every 
20 seconds in United States one person suffers from 
myocardial infarction and in every one minute a person 
dies due to MI.
2
 PCI is one of the vital treatments for 
cardiovascular patients and this method has been 
spreading impressively for treating coronary ischemic 
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Background: The mortality rate of patients with this disease is approximately 30%. Re-opening of blocked coronary 
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Methods: Among those who were randomly going for elective PCI, we selected 100 patients and divided into 2 
groups of 50 persons. In Group A, 12 hours before PCI, approximately 3 grams of omega-3, with routine medications 
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Results: The results that were obtained, show that levels of CK-MB and Troponin I raise after PCI in Group A lower 
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Conclusions: Results confirmed the effect of omega 3 in the prevention of myocardial damage caused by PCI, so we 
can use omega 3 for reducing PCI complications.  
 
Keywords: CK-MB, Troponin I, PCI, Omega 3 
1
Department of Internal Medicine, 
2
Department of Infection Disease, 
3
Social Determinants of Health (SDH) Research 
Center, 
4
General Practitioner, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran 
5
School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran  
  
Received: 28 November 2017 
Accepted: 09 December 2017 
 
*Correspondence: 
Dr. Bita Shahbazzadegan, 
E-mail: bitashahbaz2004@yahoo.com 
 
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under 
the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original work is properly cited. 
DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20180217 
Avesta L et al. Int J Community Med Public Health. 2018 Feb;5(2):443-448 
                                International Journal of Community Medicine and Public Health | February 2018 | Vol 5 | Issue 2     Page 444 
disease in all over the world for the last three decades. 
Each year one million people are being treated by PCI in 
United States which is higher than CABG.
3
 
PCI decreases mortality and myocardial infarction in 
comparison to medical treatment of coronary ischemic 
patients and also curing disease symptoms and 
ameliorating coronary ischemia by using PCI, has better 
results than medical treatment.
4
 However, numerous side 
effects (early or latent) such as hemorrhage, dissection 
sudden obstruction, thrombosis and ischemia can be 
caused by this method always. So after doing PCI, 
primary myocardial biomarkers such as CK-MB, 
troponin I and inflammatory factors like CRP rise and 
this can be a marker of escalation in cardiovascular 
incidents after PCI.
5
 Escalation of CK-MB levels about 5 
times more than normal level after using PCI method, can 
be a prediction of one year mortality escalation and also 
peri procedural MI. In patients who do not show 
symptoms only CK-MB levels rises after using PCI, 
relatively undesirable consequences may happen. I & T 
Troponin escalation after PCI is more common than 
increase in CK-MB levels, but prognostic importance of 
heart troponin escalation is yet unknown.
6
 Just one study 
has been done about this case which is also done in 
Shahid Beheshti hospital. Similar studies with this case 
haven’t been done abroad.3 
By considering this that PCI is a vital treatment for 
cardiovascular patients, at the same time it has numerous 
dangerous side effects during procedure and post 
operation side effects can be vascular dissection sudden 
obstruction, thrombosis and ischemia. By reducing these 
side effects this vital treatment can be safe and secure. 
Existing study aims to determine the effect of omega 3 
polyunsaturated fatty acids (POFA) in CK-MB and 
troponin I serum levels as a myocardial damage factor 
after using PCI. 
METHODS 
This study is a single-blind randomized clinical trial 
which had been done from date 2016/6/21 to 2016/9/10 
in heart catheterization center of Ardabil’s Imam 
Khomeini hospital. The study population was PCL 
elective candidates. Inclusion criteria included patients 
who had angioplasty indications during their 
angiography. 
Patients from any age range who were under PCI 
treatment with daily 80 mg aspirin at least from five days 
ago and patients with their own satisfaction. Exclusion 
criteria from study included: patients who needed urgent 
angioplasty, patients with kidney failure, patients treated 
with anticoagulant drugs, patients suffering from 
disorders, patients suffering from myocarditis or 
myopericarditis, patients suffering from different 
myopathies, patients treated with chemotherapy, patients 
suffering from infections. From within the patients, who 
had been candidates for elective PCI, 100 individuals 
were chosen randomly and they were divided to 2 groups 
of 50 individuals. Also randomizing was based on 
randomized numbers. Group A was treated with 3 grams 
of omega 3, 12 hours before PCI with routine drugs and 
they were also treated with 325 mg aspirin 600 mg 
clopidogrel at least 3 hours before intervention. As for 
group B, they were given placebo 12 hours before PCI 
with routine drugs. 
Data were collected after studying the experiments. 
Sampling from all of the patients was done in two rounds. 
First round, before omega 3 and placebo prescription and 
second round, 24 hours after PCI analysis of research on 
plasma levels of CK-MB and troponin I biomarkers, were 
done before and after PCI in groups A and B. The 
comparison of level changes of these biomarkers before 
and after PCI, were done individually in each group and 
the comparison of biomarkers before and after changes 
were done between both groups. Existing study has 
ethical code from ethics committee with certification 
code of IR.ARUMS.REC.1394.23. Also the IRCT 
(Iranian Registry of Clinical Trials) code of this study is 
IRCT2016072329035N1. During this study no personal 
information was leaked, no additional charges were 
imposed and informed individual consent was received 
and written from patients. 
RESULTS 
After specifying 100 patients in need of elective PCI with 
coronary angiography method and with considering 
inclusion and exclusion criteria, PCI was done on 100 
patients who were divided to two placebo and completely 
randomized omega 3 groups of 50 persons in patients of 
each group. There were approximate similarities by risk 
factors, age and gender and also there were no significant 
difference about these criteria between the patients of 
both groups. Most of the patients were men and they had 
about 45 years old. Most of the patients were suffering 
from hypertension and they have been using anti-
hypertensive drugs. Also aspirin was in prescriptions of 
most of the patients. Involved coronary vessels in the 
most of the patients in both groups were LAD and 
obtained statistics indicated almost similar conditions 
between both A and B groups. By considering the 
comparison of results of the CK-MB and troponin I, 
before and after PCI in both groups, there was a 
significant link between CK-MB and troponin I 24 hours 
after PCI and omega 3 while CK-MB P-Value and 
troponin I were higher than 0.05 in control group which 
received placebo and also they were markers of lack of 
relation between placebo and these biomarkers after PCI. 
In Table 1 patients’ distribution frequency has been 
shown according to their gender. 55% of the patients 
were male which were the majority and 45% of the 
patients were female which showed this fact that 
cardiovascular diseases were higher in male and male are 
under more coronary intervention than female. 
Distribution of male in group A (omega 3 group) was 
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52% and in group B (placebo group) was 58% and 
distribution of female in groups above respectively were 
48% and 42% which showed no significant difference 
between both groups. 
Table 1: Frequency of patients by gender. 
P value Total 
F (%) 
Placebo (B) 
F (%) 
Omega 3(A) 
F (%) Gender 
0.05 
55 (55%) 29 (58%) 26 (52%) Male 
45 (45%) 21 (42%) 24 (48%) Female 
100 (100%) 50 (100%) 50 (100%) Total 
Table 2: Frequency of patients by age. 
P value Total Placebo (B) Omega 3 (A) 
Age 
0.57 MIN Mean MAX MIN Mean MAX MIN Mean MAX 
30 49.91 69 30 51.56 68 39 48.28 69 
Table 3: Frequency of patients by variables examined. 
P value Placebo(B) Omega3(A) The variables examined 
F (%) F (%) 
0.46 12 (24) 9 (18) Smoker Smoking 
38 (76) 41 (82) Non-smoker 
0.46 5 (10) 3 (6) Yes History of coronary intervention 
45 (90) 47 (94) No 
0.14 36 (72) 29 (58) Yes Blood pressure 
14 (28) 21 (42) No 
0.42 24 (48) 28 (56) Yes History of hyperlipidemia 
26 (52) 22 (44) No 
0.67 15 (30) 17 (34) Yes History of hypercholesterolemia 
35 (70) 33 (66) No 
0.82 13 (26) 12 (24) Yes History of diabetes 
37 (74) 38 (76) No 
0.55 27 (54) 24 (48) Yes The history of aspirin 
23 (46) 26 (52) No 
0.69 3 (6) 4 (8) Yes History of myocardial infarction 
47 (94) 46 (92) No 
 
In Table 2 patients’ distribution frequency has been 
shown according to age in both groups. In general 
maximum and minimum of ages respectively were 69 
years and 30 years old. In group a middle age was 48.28 
and in group B was 51.56 which meant age similarity in 
both groups by study credibility. 
In Table 3 patients’ distribution frequency is according to 
studied variables. Smoking is one of the bold risk factors 
of cardiovascular disease. In general, 21% of patients 
were smokers and 79% were nonsmokers. In group a 
18% and in group B 24% were smokers which didn’t 
show any significant difference between both groups. 
Almost 8% of studied individuals had a history of 
previous PCI. This amount in omega 3 group was 6% and 
in control group was 10%. In general 94% didn’t have 
PCI history. Most of individuals under PCI treatment had 
hypertension and they were under treatment with anti-
hypertensive drugs. Also in this study, patients with 
hypertension were the majority. 65% of the patients had 
had hypertension which was 58% in omega 3 group and 
72% in placebo group. Hyperlipidemia and 
hypercholesterolemia are bold in causing atherosclerosis 
and most of individuals with coronary disease have 
atherosclerosis too. In this study 52% of individuals had 
hyperlipidemia and 32% had hypercholesterolemia. 
These amounts in both groups were similar and didn’t 
have any significant difference. In group A, 56% of 
patients had hyperlipidemia and 34% had 
hypercholesterolemia. In group B, 48% had 
hyperlipidemia and 30% had hypercholesterolemia. 24% 
in omega 3 group and 26% in control group were diabetic 
patients. In general, 25% were diabetic. The use of 
aspirin is common in patients with cardiovascular 
incidents and it was common in our study too. In general 
51% of patients were consuming aspirin which omega 3 
group was 48% and in control group was 54% and there 
was no significant difference between both groups. 
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As it was mentioned before, the most engaged vessel was 
LAD with 32% and the least engaged vessel was OM 
with 6%. The number of patients with both vessels 
engaged was 23%. Engaged vessels with their frequency, 
respectively are LAD>RCA>VESSEL>LCX>Diagonal> 
OM. Frequency of engaged vessels in both groups were 
similar and increases research’s credibility (Table 4). 
According to the table above, p value for engaged vessel 
in general is 0.45 which indicates no significant link 
between the engaged vessel and the results of the 
experiment. 
Table 4: Frequency of patients by involved vessel. 
Pvalue Total 
F (%) 
Placebo(B) 
F (%) 
Omega3(A) 
F (%) Involved vessel 
0.45 
32 (32) 17 (34) 15 (30) LAD 
23 (23) 12 (24) 11 (22) RCA 
9 (9) 5 (10) 4 (8) LCX 
7 (7) 3 (6) 4 (8) Diagonal 
6 (6) 3 (6) 3 (6) OM 
23 (23) 10 (20) 13 (26) Two vessel 
100 (100) 50 (100) 50 (100) Total 
Table 5: Minimum and maximum of CK-MB and troponin I 24 hours before and after PCI in control and omega 3 
group with ng/ml. 
P value Placebo(B) P value Omega3(A) 
 
 Min±SD Mean Max  Min±SD Mean Max 
0.2 10 (3.81) 15.9 23 0.2 10 (3.71) 16.8 23 PCI before CK-MB  
0.2 18 (3.75) 23.86 30 0.038 15 (3.3) 19.26 26 PCI 24 hours after CK-MB  
0.2 
0.02 
(0.011) 0.034 0.06 0.054 
0.02 
(0.007) 0.034 0.06 PCI before Troponin I  
0.054 
0.03 
(0.014) 0.07 0.1 0.003 
0.03 
(0.007) 0.035 0.05 PCI 24 hours after Troponin I  
 
Table 5 shows the minimum and maximum of CK-MB 
and troponin I 24 hours before and after PCI. By 
considering the table below we find that the measured 
amounts between both omega 3 and control group before 
PCI were similar, and CK-MB and troponin I In omega 3 
group were increased less in comparison to control group. 
This means the effect of omega 3 in reducing increased 
the effect of myocardial enzymes and as a result in 
reducing cardiovascular side effect.  
By considering similar amounts in variables above 
between both omega 3 and control group and also no 
significant difference between the amounts of both 
groups, this point can be made that the credibility of the 
study was high and results about CK-MB and Troponin I 
is accurate. 
Below 0.05 p values means significant link between 
omega 3 and results. By considering the table below p-
value (CK-MB) before PCI in both control and omega 3 
groups was 0.2. 24 hours after PCI, CK-MB p-value is 
0.038 in omega 3 group which is below 0.05 and shows 
the effectiveness of omega 3 on improvement of CK-MB 
amount after PCI. This topic is true about troponin I too. 
P-value amounts of troponin in omega 3 and placebo 
group before PCI respectively was 0.054 and 0.2 which is 
higher than 0.05. However, the post- PCI amount in 
omega 3 group was 0.003 which is below 0.05 and 
indicates the significant effectiveness of omega 3 on 
troponin after PCI. P-value (troponin and CK-MB) 
amounts 24 hours after PCI in control group respectively 
were 0.2 and 0.054 which is higher than 0.05 and indicate 
no significant link between placebo and myocardial bio 
markers after coronary intervention. In conclusion, 
omega 3 is more effective in reducing troponin I and CK-
MB enzymes than placebo and also it is effective in 
reducing cardiovascular side effects after PCI. 
DISCUSSION 
This randomized clinical trial showed that omega 3 can 
lower the CK-MB and troponin I levels after PCI in 
comparison to control group which has received placebo. 
Infarction and myonecrosis were the most common 
reasons of death due to coronary interventions (PCI). The 
occurrence and amount of myocardial damage after PCI 
is very variable. Different factors have effect on them 
such as: angiographic features, intervention procedure, 
and the patients’ history, adjuvant drug therapy after PCI 
and biomarkers and used threshold for identifying 
myocardial injuries. According to ACC classification, the 
escalation of myocardial enzymes (CK-MB and 
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Troponin1) to more than 3 times normal is the marker of 
myocardial infarction and about 1 to 3 times more than 
normal is myocardial necrosis. Although there are some 
primary studies done but it was believed that these 
myocardial biomarkers rise was just a simple leak and it 
didn’t have long term effects. But recent studies persist 
on short-term, average and long term effects of 
myocardial enzymes on the escalation of post PCI 
mortality. So AHA/ACC guide line suggests routine 
measurements of CK-MB and troponin during 8-12 hours 
after PCI in all the patients without considering 
symptoms for assessment of prognosis. The clinical 
significance and prognosis of biomarkers escalation has 
been shown in several studies. However exudation of 
post PCI myocardial enzymes is debatable. Several 
studies have shown that slight increase on CK-MB has 
effect on the rise of patients mortality treated by PCI. 
In a study which was done on 2265 patients treated with 
PCI. It was found that atheromatous plaques can 
significantly anticipate the post PCI, CK-MB escalation. 
There was linear link between post PCI CCK-MB 
escalation and mortality.
7
 Several studies have been done 
about prognostic importance of troponin around PCI. 
However the prognostic value of post PCI troponin 
escalation without CK-MB escalation is notable. Older 
studies do not show any link between post PCI troponin 
escalation and mortality in long term. Recent studies have 
shown that troponin I escalation without CK-MB in 
patients treated with PCI elective was very common and 
it didn’t have any link with hospital mortality escalation. 
However, the escalation in troponin I levels can be 
individually related to mortality risk in long term to 5 
times more than normal upper limit.
8
 
Generally the escalation of myocardial biomarkers is the 
indicative of systemic and unstable atherosclerosis which 
is a predisposing factor of patient to ischemic incidence 
in future. By considering post PCI myonecrosis risk some 
studies have been done for reaching useful 
pharmacological interventions, in order to reduce this 
side effect. Due to high possibility of post PCI recurrent 
ischemic incidents by inefficient platelet inhibition, 
several studies have been done around anti platelet 
treatment as a therapeutic option. Nowadays anti platelet 
treatment with using both aspirin and clopidogrel by 
adding heparin is the most common anti thrombotic 
strategy in PCI reducing ischemic complications in 
intervention.  
It has been proved that adding high doses of statin (80 mg 
atherostatin) in patient suffering from non ST elevated 
ACS before PCI, is accompanied with reduction of heart 
related complications in long term In comparison with 
patients who were not receiving statin before PCI. 
Several studies have proved anti platelet and anti-
inflammatory effects omega 3. High daily doses of EPA 
(more than 3 gr) with DHA can improve cardiovascular 
risk factors by reducing triacylglycerol, blood pressure, 
platelet aggregation and inflammation. Some of the 
researches have studied omega 3 anti-platelet effects. 
Previous studies have shown that prescription of higher 
doses DHA can reduce platelet aggregation by collagen 
production. A study showed that lower doses of DHA 
(400-800 mg per day) significantly reduce platelet 
function. Several studies have shown the benefits of 
omega 3 in preventing stenosis after angioplasty. 
Also studies have done about beneficial effects of omega 
3 on CRP in variety of patients like hemodialysis patient 
which CRP reduction. Our results showed that 3 gr 
omega 3, single dose, 12 hours before PCI can reduce 
increased levels of troponin I and CK-MB 24 hours after 
PCI. This effect can be explained by different anti platelet 
mechanisms and omega 3 anti-inflammatory effects. 
Because both antiplatelet and anti-inflammatory effects 
have an important role in atherosclerosis pathogenesis 
Therefor by considering direct link increased plasma 
levels of CK-MB and troponin I with high risk of 
cardiovascular incident after omega 3 PCI can have 
protective effect from post PCI cardiovascular incidents.
9
 
In previous studies about omega 3 effects on myocardial 
biomarkers, even though troponin I reduction was 
expected, but there were no difference in troponin I levels 
between control group and the group which received 
omega 3. But in this study post PCI omega 3 effects on 
reducing increased biomarkers (CK-MB and Troponin I) 
in comparison to a group which received placebo. 
Confirms omega 3 is positive effects on reducing post 
PCI complications.
8
 In this study sample size was larger 
than previous study and there was no diagnostic limit in 
troponin I measurement kits. Also in previous studies 
patients with high cardiac enzymes before PCI were out 
of the study. Also in this study the patients with high 
cardiac enzymes before PCI were not used in clinical 
trial, these patients have higher risks for post PCI 
cardiovascular complications and they are likely to 
benefit more from clinical trial in comparison to other 
patients.
6
 Limited financial resources and having not 
enough facilities for evaluating other cardiovascular 
injury enzymes and limited statistical society are 
limitations of this study. 
CONCLUSION  
Results confirm the use of omega 3 in preventing 
myocardial injuries; therefore it seems that cardiovascular 
complications of PCI can be decreased. 
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